key inclusion criteria: 1. laboratory-confirmed severe acute respiratory syndrome (sars)-cov-2 infection (positive reverse transcription-polymerase chain reaction \[rt-pcr\] test or other authorized antigen testing methods) in any samples following local practice ≤ 72 hours prior to screening. 2. have experienced covid-19 symptoms for ≤ 7 days prior to treatment assignment, such as fever, cough, shortness of breath, sore throat, diarrhea, vomiting, and dysgeusia 3. agree to the collection of nasopharyngeal swabs, saliva, and venous blood key

key inclusion criteria: 1. laboratory-confirmed severe acute respiratory syndrome (sars)-cov-2 infection (positive reverse transcription-polymerase chain reaction \[rt-pcr\] test or other authorized antigen testing methods) in any samples following local practice ≤ 72 hours prior to screening. 2. have experienced covid-19 symptoms for ≤ 7 days prior to treatment assignment, such as fever, cough, shortness of breath, sore throat, diarrhea, vomiting, and dysgeusia 3. agree to the collection of nasopharyngeal swabs, saliva, and venous blood key

key inclusion criteria: laboratory-confirmed severe acute respiratory syndrome (sars)-cov-2 infection (positive reverse transcription-polymerase chain reaction [rt-pcr] test or other authorized antigen testing methods) in any samples following local practice ≤ 72 hours prior to screening. have experienced covid-19 symptoms for ≤ 7 days prior to treatment assignment, such as fever, cough, shortness of breath, sore throat, diarrhea, vomiting, and dysgeusia agree to the collection of nasopharyngeal swabs, saliva, and venous blood key

key inclusion criteria: laboratory-confirmed severe acute respiratory syndrome (sars)-cov-2 infection (positive reverse transcription-polymerase chain reaction [rt-pcr] test or other authorized antigen testing methods) in any samples following local practice ≤ 72 hours prior to screening. have experienced covid-19 symptoms for ≤ 7 days prior to treatment assignment, such as fever, cough, shortness of breath, sore throat, diarrhea, vomiting, and dysgeusia agree to the collection of nasopharyngeal swabs, saliva, and venous blood key

key inclusion criteria: 1. laboratory-confirmed severe acute respiratory syndrome (sars)-cov-2 infection (positive reverse transcription-polymerase chain reaction [rt-pcr] test or other authorized antigen testing methods) in any samples following local practice ≤ 72 hours prior to screening. 2. have experienced covid-19 symptoms for ≤ 7 days prior to treatment assignment, such as fever, cough, shortness of breath, sore throat, diarrhea, vomiting, and dysgeusia 3. agree to the collection of nasopharyngeal swabs, saliva, and venous blood key

key inclusion criteria: 1. laboratory-confirmed severe acute respiratory syndrome (sars)-cov-2 infection (positive reverse transcription-polymerase chain reaction [rt-pcr] test or other authorized antigen testing methods) in any samples following local practice ≤ 72 hours prior to screening. 2. have experienced covid-19 symptoms for ≤ 7 days prior to treatment assignment, such as fever, cough, shortness of breath, sore throat, diarrhea, vomiting, and dysgeusia 3. agree to the collection of nasopharyngeal swabs, saliva, and venous blood key